Early access
Sign in
Taking people in United StatesPhase 2

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Key facts

Who runs it
AbbVie
Where
Allentown, Anaheim, Avon Lake, Bellevue, Brooklyn, Charleston, Charlotte, Chicago, Cincinnati, Colton, Columbus, Cromwell, Dallas, Everett, Franklin, Gaithersburg, Huntsville, Imperial, Jacksonville, Largo, Las Vegas, Lemon Grove, Long Beach, Los Angeles, Maitland, Marietta, Miami, O'Fallon, Oceanside, Oklahoma City, Orlando, Overland Park, Phoenix, Princeton, Richmond, Saint Charles, Savannah, Springfield, St Louis, Temecula, The Woodlands, Toms River, Tucson, Walnut Creek, West Chester, and Wichita Falls, United StatesSee the 49 sitesAlso in 1 other country, 3 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
315 people, planned
Started
29 Apr 2025
Expected to end
Nov 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ABBV-932
  • Placebo for ABBV-932
  • Antidepressant Therapy (ADT)
Record updated
17 June 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Currently taking protocol-specified antidepressant therapies (ADT) for GAD with an inadequate response to an adequate dose (per label) and duration (>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score >= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) >= 4

Who cannot take part

  • Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score >= 20
  • New diagnosis or exacerbation of major depression in the last 6 months

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

Also in 1 other country, 3 sites

  • Lehigh Center for Clinical Research /ID# 267908Allentown, United StatesTaking people
  • Advanced Research Center /ID# 267874Anaheim, United StatesContact: Site CoordinatorTaking people
  • Quest Therapeutics of Avon /ID# 267829Avon Lake, United StatesContact: Site CoordinatorTaking people
  • Northwest Clinical Research Center /ID# 267916Bellevue, United StatesTaking people
  • Integrative Clinical Trials /ID# 279519Brooklyn, United StatesTaking people
  • Coastal Carolina Research Center, LLC /ID# 267826Charleston, United StatesContact: Site CoordinatorTaking people
  • New Hope Clinical Research - Inpatient unit /ID# 267810Charlotte, United StatesContact: Site CoordinatorTaking people
  • University of Chicago Medical Center /ID# 275131Chicago, United StatesTaking people
  • University Of Cincinnati Medical Center /ID# 271704Cincinnati, United StatesTaking people
  • Axiom Research /ID# 267814Colton, United StatesContact: Site CoordinatorTaking people
  • The Ohio State University /ID# 267924Columbus, United StatesTaking people
  • Connecticut Clinical Research - Cromwell /ID# 271241Cromwell, United StatesTaking people
  • FutureSearch Trials of Dallas /ID# 267870Dallas, United StatesTaking people
  • Relaro Medical Trials /ID# 270241Dallas, United StatesTaking people
  • Core Clinical Research /ID# 270058Everett, United StatesTaking people
  • Psychiatric Consultants - Franklin /ID# 275133Franklin, United StatesContact: Site CoordinatorTaking people
  • CenExel /ID# 267853Gaithersburg, United StatesContact: Site CoordinatorTaking people
  • University of Alabama - Huntsville Regional Medical Campus /ID# 267818Huntsville, United StatesContact: Site CoordinatorTaking people
  • Sun Valley Research Center /ID# 267864Imperial, United StatesContact: Site CoordinatorTaking people
  • Cns Healthcare - Jacksonville /ID# 268588Jacksonville, United StatesTaking people
  • Accel Research Sites Network - St. Pete /ID# 267821Largo, United StatesContact: Site CoordinatorTaking people
  • Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 275731Las Vegas, United StatesTaking people
  • Duplicate_Oasis Clinical Research, LLC /ID# 267953Las Vegas, United StatesNo longer taking part
  • Synergy San Diego /ID# 267879Lemon Grove, United StatesTaking people
  • Alliance for Research Alliance for Wellness /ID# 267911Long Beach, United StatesTaking people
  • NRC Research Institute DTLA /ID# 267832Los Angeles, United StatesContact: Site CoordinatorTaking people
  • K2 Medical Research, LLC /ID# 267841Maitland, United StatesTaking people
  • Psych Atlanta /ID# 267878Marietta, United StatesTaking people
  • Allied Biomedical Res Inst Inc /ID# 267813Miami, United StatesContact: Site CoordinatorTaking people
  • GMI Florida - Central Miami Medical Institute /ID# 267839Miami, United StatesContact: Site CoordinatorTaking people
  • Psychiatric Care And Research Center /ID# 271701O'Fallon, United StatesTaking people
  • Excell Research /ID# 267918Oceanside, United StatesTaking people
  • Sooner Clinical Research /ID# 267881Oklahoma City, United StatesTaking people
  • Apg Research /ID# 271707Orlando, United StatesTaking people
  • Collective Medical Research /ID# 272015Overland Park, United StatesTaking people
  • Ima Clinical Research Phoenix (Alea) /ID# 275737Phoenix, United StatesTaking people
  • Princeton Medical Institute /ID# 267877Princeton, United StatesContact: Site CoordinatorTaking people
  • Perceptive Pharma Research /ID# 267836Richmond, United StatesContact: Site CoordinatorTaking people
  • Saint Charles Psychiatric Associates /ID# 271202Saint Charles, United StatesTaking people
  • iResearch Savannah /ID# 267865Savannah, United StatesContact: Site CoordinatorTaking people
  • Elixia - Springfield /ID# 267815Springfield, United StatesTaking people
  • Arch Clinical Trials /ID# 267851St Louis, United StatesTaking people
  • Inland Psychiatric Medical Group /ID# 268598Temecula, United StatesTaking people
  • Family Psychiatry Of The Woodlands /ID# 275173The Woodlands, United StatesTaking people
  • Bio Behavioral Health /ID# 267919Toms River, United StatesTaking people
  • Noble Clinical Research /ID# 267952Tucson, United StatesNo longer taking part
  • Sunwise Clinical Research /ID# 267863Walnut Creek, United StatesContact: Site CoordinatorTaking people
  • Suburban Research Associates /ID# 267868West Chester, United StatesContact: Site CoordinatorTaking people
  • Grayline Research Center /ID# 267811Wichita Falls, United StatesContact: Site CoordinatorTaking people

About the trial

What the trial wants to find out

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.

Read full original descriptionShow less

ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico.

Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

The 3 groups in the trial

  • ABBV-932 Dose ATreatment being tested

    Participants will receive ABBV-932 dose A in addition to prescribed antidepressant therapies (ADTs).

    Treatment: ABBV-932 and Antidepressant Therapy (ADT)

  • ABBV-932 Dose BTreatment being tested

    Participants will receive ABBV-932 dose B in addition to prescribed antidepressant therapies (ADTs).

    Treatment: ABBV-932 and Antidepressant Therapy (ADT)

  • Placebo for ABBV-932Placebo, for comparison

    Participants will receive placebo for ABBV-932 in addition to prescribed antidepressant therapies (ADTs).

    Treatment: Placebo for ABBV-932 and Antidepressant Therapy (ADT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies
Fit questions
Built from NCT06846320, who can take part
Record updated
17 June 2026